Produce sufficient additional MAB114 drug substance (DS) and drug product (DP) batches that adhere to cgmp compliance and product quality release criteria, and which meet the anticipated clinical…
Ended Awarded Last action
- Contract number
- 75N91019F00133
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,417,445
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $4,417,445.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $4,417,445 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is valued at $4,417,445.00 and is for the production of additional batches of the MAB114 drug substance and drug product that meet current good manufacturing practice (CGMP) compliance and quality release criteria. This work is in support of ongoing and planned clinical trials for the MAB114 Ebola monoclonal antibody product. The contract does not have a set-aside designation and is scheduled for completion on July 31, 2024. Leidos Biomedical Research has provided a range of biomedical research and production services to federal agencies, particularly the NIH, through past prime and subcontract awards.
Description
Produce sufficient additional MAB114 drug substance (DS) and drug product (DP) batches that adhere to cgmp compliance and product quality release criteria, and which meet the anticipated clinical demand for ongoing and planned clinical trials.
Quick answers
Who was awarded contract 75N91019F00133?
75N91019F00133 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 2, 2019.
How much is contract 75N91019F00133 worth?
The government has obligated $4,417,445 on 75N91019F00133.
Which agency awarded contract 75N91019F00133?
National Cancer Institute (National Institutes of Health) awarded 75N91019F00133, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91019F00133 an order under another contract?
Yes. 75N91019F00133 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91019F00133 competed?
The extent of competition for 75N91019F00133 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award